Drug Discovery Clinic
Developing novel therapies to address infectious disease and cancer.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
* | €1.5m | Seed | |
| Total Funding | 000k | ||
| EUR | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (35 %) | 82 % | 729 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 5 % | (239 %) | (399 %) | 24 % |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
DDC Pharmaceutical focuses on the development of Dihydroorotate Dehydrogenase (DHODH) inhibitors, targeting the treatment of Acute Myeloid Leukemia (AML) and COVID-19. The company aims to bring its leading molecule to clinical trials within the next 1 to 2 years. DDC operates in the pharmaceutical industry, serving patients and healthcare providers by developing new drug candidates. The business model revolves around pharmaceutical research and development, with revenue generated through the successful commercialization of its drug candidates. The company leverages a multidisciplinary team of experts in drug development and clinical research to accelerate the drug discovery process and improve patient outcomes. DDC's approach combines scientific rigor with innovative methodologies to deliver effective treatments faster.
Keywords: DHODH inhibitors, AML treatment, COVID-19 therapy, clinical trials, pharmaceutical development, drug discovery, multidisciplinary team, innovative solutions, patient outcomes, healthcare providers.